The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Synedgen Receives $119 Million Contract from BARDA to Develop MIIST305 as Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome
Oct 15, 2024•over 1 year ago
Contract Type
contract
ClaremontHealthcareHealth Care
Description
Synedgen, Inc. has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA), valued at up to $119 million over a six-year period. This contract aims to develop Synedgen’s lead therapeutic, MIIST305, to address Gastrointestinal Acute Radiation Syndrome (GI-ARS) arising from acute exposure to ionizing radiation.
Company Information
Company
Synedgen
Location
1420 N. CLAREMONT BOULEVARD
Claremont, California, United States
About
Synedgen, Inc. is a biotechnology company developing Multivalent Innate Immune Signaling Target (MIIST) therapeutics that modulate and enhance the innate immune system. The company’s lead development candidate is MIIST305, an oral, glycocalyx targeted induction and maintenance therapy for ulcerative colitis (UC). With US Government support, MIIST305 is also being developed in parallel as a medical countermeasure (MCM) for gastrointestinal acute radiation syndrome (GI-ARS). MIIST technology has been validated with clinical trials in partnered programs and extensively peer-reviewed through twenty-two (22) National Institutes of Health grants and Department of Defense contracts. Synedgen has an in-house GMP manufacturing facility.
ClaremontHealthcareHealth Care